Conversely, WT1 is frequently overexpressed in AML, MDS, and blast crisis of chronic myeloid leukemia, and expression levels are associated with increased blast counts, higher risk of progression and relapse, resistance to therapy, and poor OS [11,14,15,16,17]. Here, WT1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.